The tAnGo fell short of inspiring the audience
Mené sur 3 152 patientes atteintes d'un cancer du sein de stade précoce, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de l'ajout de gemcitabine à une chimiothérapie adjuvante combinant paclitaxel, épirubicine et cyclophosphamide (durée médiane de suivi : 10 ans)
Advances in medical therapeutics rely on proper clinical experimentation, and not infrequently we are disappointed by negative results. This is especially true for the open-label, randomised controlled tAnGo study,1 which, at the time it was conceived, was expected to show a successful development in adjuvant therapy for early breast cancer. Based on proof-of-survival benefit with the combination of gemcitabine and paclitaxel in the metastatic setting,2 the tAnGo study explored the efficacy of adding gemcitabine to anthracycline-based and taxane-based adjuvant chemotherapy (epiribicin and cyclophosphamide followed by paclitaxel) in women with moderate- or high-risk early breast cancer.
The Lancet Oncology , commentaire, 2016